Wednesday, February 14, 2018 10:15 PM ET
Insider Selling at Blueprint Medicines (BPMC) Continues with Significant Sale
There was a notable insider sale of Blueprint Medicines shares today, as revealed in a filing with the SEC as — Daniel Lynch, Director — sold 17,500 shares in the company having a market value of approximately $1,309,668 There was one insider buy/sell transaction in the past 90 days prior to this transaction which resulted in the sale of 5,000 shares. Adding the most recent activity to this 90-day history indicates insider trades have been net sales of 22,500 shares and have averaged 11,250 shares per transaction over this time period.
Over the last 90 days, the number of insider buy/sell trades at Blueprint Medicines is above its 191-company peer group average. The Biotechnology & Medical Research peer group saw 162 buy/sell trades during this period for an average of 0.8 transactions per company. However, the number of shares traded per transaction by Blueprint Medicines insiders is lower than its peers. Within the peer group there were 13,661,476 shares purchased and 12,687,858 shares sold with company insiders having bought 8,851 shares on average over this time period.
To bring into focus significant insider buying and selling activity, all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers has been eliminated in data used to evaluate and write this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2018 UpTick Data Technologies. All rights reserved.